Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Net Income: 2009-2025

Historic Net Income for Madrigal Pharmaceuticals (MDGL) over the last 12 years, with Sep 2025 value amounting to -$111.1 million.

  • Madrigal Pharmaceuticals' Net Income fell 3.88% to -$111.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$286.0 million, marking a year-over-year increase of 44.86%. This contributed to the annual value of -$465.9 million for FY2024, which is 24.69% down from last year.
  • Madrigal Pharmaceuticals' Net Income amounted to -$111.1 million in Q3 2025, which was down 163.07% from -$42.2 million recorded in Q2 2025.
  • Madrigal Pharmaceuticals' 5-year Net Income high stood at -$42.2 million for Q2 2025, and its period low was -$152.0 million during Q2 2024.
  • Moreover, its 3-year median value for Net Income was -$98.7 million (2023), whereas its average is -$96.9 million.
  • In the last 5 years, Madrigal Pharmaceuticals' Net Income tumbled by 91.87% in 2024 and then surged by 72.21% in 2025.
  • Over the past 5 years, Madrigal Pharmaceuticals' Net Income (Quarterly) stood at -$64.5 million in 2021, then crashed by 33.08% to -$85.9 million in 2022, then crashed by 30.60% to -$112.2 million in 2023, then surged by 47.04% to -$59.4 million in 2024, then declined by 3.88% to -$111.1 million in 2025.
  • Its Net Income was -$111.1 million in Q3 2025, compared to -$42.2 million in Q2 2025 and -$73.2 million in Q1 2025.